Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-103; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 11
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

Conditions: COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
Interventions: RQ-001, Placebo; Combination Product · Other
Lead sponsor: Red Queen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more

Conditions: Obesity
Interventions: LIK066, Carbohydrate 50%, Carbohydrate 25%, Carbohydrate 8%, Carbohydrate 0%, Psyllium, Calcium carbonate; Drug · Dietary Supplement
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Macular Degeneration
Interventions: 0.5 mg ranibizumab; Drug
Lead sponsor: Charles C Wykoff, PhD, MD; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more

Conditions: Idiopathic Hyperbilirubinemia, Neonatal Hyperbilirubinemia, Prematurity
Interventions: Phototherapy, glycerin suppository; Procedure · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 30 Weeks to 35 Weeks
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Inflammatory Bowel Diseases, Short Bowel Syndrome, Ileostomy - Stoma
Interventions: amino acid mixture beverage, glucose-based sports drink; Other
Lead sponsor: Entrinsic Bioscience Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashua, New Hampshire • Chapel Hill, North Carolina

Conditions: Prostate Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry; Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 40 Years to 120 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions: Genetic Testing; Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Opiates, Healthy
Interventions: Vicks VapoInhaler, Poppy seeds; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Use, Opioid Use Disorder, Cocaine Use, Cocaine Use Disorder
Interventions: DynamiCare Health, Methadone Treatment-As-Usual; Behavioral · Drug
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Baltimore, Maryland

Conditions: Bariatric Surgery Candidate, Postoperative Nausea and Vomiting, Morbid Obesity
Interventions: Bariatric Full Liquid Diet; Dietary Supplement
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Adults, Atopic Dermatitis, Wearables, Sweat Sensor, Gas Sensor
Interventions: Gas sensor, Sweat Sensor; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ischemic and Non-ischemic Cardiomyopathy
Interventions: Medtronic ICD with Opti Vol-Monitor; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pain, Inflammatory Response
Interventions: Moderate Fat Meal, High Fat Meal; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity, Overweight, Diabetes
Interventions: food in fluid form, food in solid form; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Organ Transplantation From Brain-dead Donors
Interventions: Cold isotonic fluid and central venous hypothermia catheter; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Covid19
Interventions: ASA; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Tobacco-Related Carcinoma
Interventions: Biospecimen Collection, Carbon Monoxide Measurement, Vaping session, Survey Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Postoperative Pain, Shoulder Pain
Interventions: Instillation of Bupivacaine with epinephrine over the diaphragm; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid-use Disorder, Stress Related Disorder, Anxiety, Pain Interference
Interventions: Live-Online M-ROCC, Live-Online Control; Behavioral
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: U3-1287, Erlotinib, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more

Conditions: Idiopathic Intracranial Hypertension
Interventions: Acetazolamide, Optic Nerve Sheath Fenestration, Ventriculoperitoneal CSF Shunting; Drug · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 63 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 33
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 26 more

Search by objective public record fields.

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

Glycerin Suppositories to Reduce Jaundice in Premature Infants

Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Factors Affecting Methamphetamine and Opiates Drug Testing

Treating Polysubstance Use Using a Novel Digital Technology

Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery

Sweat and Gas Sensor for Healthy Skin and Atopic Dermatitis

OptiVol for Precision Medical Management of Heart Failure

Association Between Body Composition and Pain in Spinal Cord Injury

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Food Rheology and Feeding in Lean and Obese Humans

Cooling to Optimize Organ Life in Donor Study

Outpatient Liquid Aspirin (OLA)

Manipulating E-Cigarette Nicotine to Promote Public Health

Bupivacaine With Epinephrine Over Diaphragm in Laparoscopy

Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Surgical Idiopathic Intracranial Hypertension Treatment Trial